Real-World study shows tofacitinib helps control psoriatic arthritis
NCT ID NCT04517669
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study followed 116 adults with moderate to severe psoriatic arthritis who were starting tofacitinib as part of their normal care. Researchers tracked disease activity, remission rates, and quality of life over 12 months. The goal was to see how well the drug works in real-world settings, not just in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AZ Sint-Jan
Bruges, 8000, Belgium
-
Algemeen Stedelijk Ziekenhuis
Aalst, 9300, Belgium
-
Barzilai Medical Center
Ashkelon, Israel
-
Bnai Zion Medical Center
Haifa, 31048, Israel
-
C.H. Universitario de Vigo- Hospital Meixoeiro
Vigo, Galicia, 36200, Spain
-
CHR Orleans
Orléans, 45067, France
-
CHU Besançon - Hôpital Jean Minjoz
Besançon, 25000, France
-
CHU Clermont Ferrand - Hopital Gabriel Montpied
Clermont-Ferrand, 63000, France
-
CHU Tours - Hôpital Trousseau
Tours, 37044, France
-
Centre Hospitalier Jean Rougier
Cahors, 46000, France
-
Chaim Sheba Medical Center
Ramat Gan, 52621, Israel
-
Galilee Medical Center
Nahariya, Israel
-
Hadassah Hebrew University Medical Center - Ein Kerem
Jerusalem, 91120, Israel
-
Hadassah University Hospital - Ein Kerem
Jerusalem, 246000, Israel
-
Hopital Pasteur
Nice, 6001, France
-
Hopital Purpan
Toulouse, 31059, France
-
Hospital Quironsalud Infanta Luisa
Seville, 41010, Spain
-
Hospital Regional Universitario de Malaga
Málaga, 29010, Spain
-
Hospital Universitario Central de Asturias
Oviedo, 33011, Spain
-
Hospital Universitario Puerta del Mar
Cadiz, 11009, Spain
-
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
-
Hospital Universitario San Cecilio
Granada, 18012, Spain
-
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
-
Hospital Universitario Virgen de las Nieves
Granada, 18014, Spain
-
Hospital de Especialidades de Jerez de la Frontera
Cadiz, 11407, Spain
-
Infirmerie Protestante de Lyon
Caluire-et-Cuire, 69300, France
-
Karolinska University Hospital, Solna
Stockholm, Sweden
-
Lund University
Lund, Sweden
-
Medisch Centrum Leeuwarden
Leeuwarden, Netherlands
-
Medisch Spectrum Twente, Haaksbergerstraat
Enschede, 7512 KZ, Netherlands
-
Norrlands University Hospital Umeå, Reumatologiska kliniken Västerbotten
Umeå, Sweden
-
Nova Reuma Społka Partnerska
Genk, 3600, Belgium
-
Rambam Health Care Center
Haifa, Israel
-
Sheba Medical Center
Ramat Gan, Israel
-
Skånes Universitetssjukhus, Malmö
Malmö, Sweden
-
Soroka University Medical Center
Beersheba, 84001, Israel
-
Sygehus Vendsyssel Hospital
Hjørring, Denmark
-
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
-
The Baruch Padeh Medical Center - Poriya
Tiberias, 15208, Israel
-
The Lady Davis Carmel Medical Center
Haifa, 3436212, Israel
-
Turku University Hospital
Turku, Finland
Conditions
Explore the condition pages connected to this study.